BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control Tough-to-Treat blood cancer
Disease control OngoingThis study is testing a multi-step treatment plan for adults with a specific, aggressive form of leukemia (ALL) that has come back or hasn't responded to prior therapy. The plan combines lower-intensity chemotherapy with two targeted drugs, ponatinib and blinatumomab, to attack t…
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Triple-Threat attack on tough leukemias shows promise
Disease control OngoingThis study is testing whether combining three different cancer drugs can better control two aggressive types of blood cancer: Philadelphia chromosome-positive acute myeloid leukemia (AML) and advanced chronic myeloid leukemia (CML). The trial will enroll about 20 adults with thes…
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New antibody drug enters human testing for Tough-to-Treat blood cancers
Disease control OngoingThis is a first-in-human study to find a safe dose of an experimental antibody drug called Hu8F4 for patients with advanced blood cancers like leukemia and myelodysplastic syndrome (MDS). The main goals are to check for side effects and see how the body processes the drug. The st…
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug combo tested for Tough-to-Treat leukemia
Disease control OngoingThis study is testing a combination of intensive chemotherapy (called Hyper-CVAD) and a targeted drug called ponatinib for adults with a specific type of acute lymphoblastic leukemia (ALL) that involves a genetic change called Philadelphia chromosome or BCR-ABL. The main goal is …
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC